Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 64980-746

9 FDA label images from Rising Pharma Holdings, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 64980-746). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structure (Alfuzosin Str)

Structure (Alfuzosin Str)
Chemical structure of the active ingredient Alfuzosin Hydrochloride, showing its molecular components including aromatic rings, amine groups, and hydrochloride salt.*
FDA Label Image

Figure-1 (Alfuzosin Fig1)

Figure-1 (Alfuzosin Fig1)
A pharmacokinetic line graph showing alfuzosin plasma concentration (ng/mL) over time (hours) for fed and fasted conditions. Plasma levels rise more rapidly and reach higher peak concentrations under fed conditions compared to fasted, with concentration decreasing after about 10 hours through 24 hours. Error bars representing variability are included for each time point.*
FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)
A line graph depicting mean change from baseline in IPSS total symptom score over days of treatment comparing Alfuzosin Hydrochloride (10 mg) and placebo groups. The x-axis shows days of treatment (0, 28, 56, 84), and the y-axis shows mean change with a decreasing trend indicating symptom improvement, showing greater reduction in symptoms for Alfuzosin Hydrochloride compared to placebo over time.*
FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)
Line graph depicting the mean change from baseline in IPSS total symptom score over 84 days of treatment comparing placebo (N=152) and Alfuzosin Hydrochloride (N=137). The y-axis shows mean change, with Alfuzosin Hydrochloride showing a greater decrease in symptom score over time compared to placebo.*
FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)
A line graph depicting the mean change from baseline in IPSS Total Symptom Score over days of treatment, comparing Alfuzosin Hydrochloride with placebo. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows mean change values. Two lines show symptom score changes for placebo and Alfuzosin Hydrochloride groups during a clinical trial.*
FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)
A line graph showing the mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment. It compares two groups: Placebo and Alfuzosin Hydrochloride, with the Alfuzosin group showing a higher mean increase sustained over time. The x-axis represents days of treatment, and the y-axis shows the mean change in mL/s.*
FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over days of treatment, comparing Alfuzosin Hydrochloride and placebo groups. The x-axis represents days of treatment (0, 14, 28, 56, 84), and the y-axis represents mean change in mL/s. Alfuzosin Hydrochloride shows a greater increase than placebo throughout the treatment period.*
FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over days of treatment up to 84 days comparing Alfuzosin Hydrochloride with placebo. The graph plots mean change on the y-axis and days of treatment on the x-axis, illustrating treatment effects over time for two groups (Alfuzosin Hydrochloride and placebo).*
FDA Label Image

Figure (Alfuzosin Fig8)

Figure (Alfuzosin Fig8)
Alfuzosin Hydrochloride 10 mg extended-release film-coated tablets label from Rising Pharma Holdings, Inc. The label indicates 90 tablets in the package and emphasizes swallowing tablets whole without chewing or crushing. Storage instructions specify temperature ranges, and the product is noted as made in India and for prescription use only (Rx only).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.